Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other endocrine-driven cancers. The news flow around OLMA reflects its active clinical development program, capital markets activity, and ongoing corporate updates.
Investors and followers of Olema’s news can expect frequent updates on its lead product candidate, palazestrant (OP-1250), an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) being evaluated in ER+/HER2- metastatic breast cancer. Company announcements include progress in pivotal Phase 3 trials such as OPERA-01 and OPERA-02, data presentations from Phase 1b/2 studies of palazestrant in combination with ribociclib, and details on additional Phase 1/2 combination studies with agents like palbociclib, alpelisib, everolimus, and atirmociclib.
Olema’s news stream also covers pipeline developments for OP-3136, a KAT6 inhibitor in Phase 1 clinical evaluation as monotherapy and in combination with fulvestrant and palazestrant in advanced solid tumors. Regulatory and collaboration milestones, such as clinical trial agreements with Pfizer to study palazestrant plus atirmociclib, are disclosed through press releases and SEC filings.
In addition, Olema regularly reports financial and operating results, underwritten public offerings of common stock under its shelf registration on Form S-3, and inducement grants of stock options to new employees under its 2022 Inducement Plan. The company also announces participation in healthcare and investor conferences, where it presents updates on its clinical programs and strategy. Readers who follow OLMA news gain insight into trial progress, collaboration agreements, financing activities, and other corporate events that shape Olema’s development as a clinical-stage oncology company.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to four new employees to purchase an aggregate of 205,000 shares, effective March 2, 2026.
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term and an exercise price of $24.02, equal to the last reported Nasdaq sale price on March 2, 2026.
Olema Oncology (Nasdaq: OLMA) announced that CEO Sean P. Bohen, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 p.m. ET. A live webcast and recording will be available on Olema’s investor relations site, subject to event host permissions.
Olema Oncology (Nasdaq: OLMA) announced participation in three investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 11 (New York, fireside chat), Citi’s Virtual Oncology Leadership Summit on Feb 19 (virtual, fireside chat), and Oppenheimer Healthcare Life Sciences on Feb 26 (virtual, fireside chat). Live webcasts and recordings will be posted at Olema's investor relations site, as permitted by event hosts.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 24,000 shares, effective February 2, 2026. The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $25.65.
The awards were approved by the Compensation Committee and issued under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA) announced that Shane Kovacs, Chief Operating and Financial Officer, is departing effective January 30, 2026 to pursue new opportunities and will remain as a consultant through August 1, 2026. The company has begun an immediate search for a successor, and President and CEO Sean P. Bohen, M.D., Ph.D., has assumed the role of interim Principal Financial Officer.
The release notes Kovacs helped advance palazestrant to late-stage clinical development, build a finance team, and establish a strong capital position.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to 8 new employees to purchase an aggregate of 223,500 shares, effective January 2, 2026.
The awards were approved under Olema's 2022 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). Options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $25.28 per share — equal to the last reported Nasdaq sale price on January 2, 2026. Awards are subject to plan terms and continuous employment for vesting.
Olema Oncology (Nasdaq: OLMA) announced that Sean P. Bohen, M.D., Ph.D., President and CEO will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2025 at 11:15 a.m. PT (2:15 p.m. ET).
A live webcast and any accompanying presentation materials will be accessible in the Events and Presentations section of Olema's investor relations website at ir.olema.com, and a recording will be posted after the event.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 65,000 shares, effective December 1, 2025. The awards were approved by the Compensation Committee under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $27.95 per share, equal to the last reported Nasdaq sale price on December 1, 2025. The grants are subject to the Inducement Plan terms.
Olema Oncology (Nasdaq: OLMA) will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET. The company is a clinical-stage biopharmaceutical focused on targeted therapies for breast cancer and related indications.
Live webcasts and recordings will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
Olema Oncology (Nasdaq: OLMA) closed an underwritten public offering of 11,500,000 common shares, including the full exercise of the underwriters' option to purchase 1,500,000 additional shares, at $19.00 per share.
Gross proceeds to Olema, before underwriting discounts, commissions and estimated offering expenses, were approximately $218.5 million. The offering relied on a shelf registration on Form S-3 declared effective January 15, 2025 and a related Form S-3MEF filed and automatically effective on November 18, 2025. Book-running managers included TD Cowen, Evercore ISI, Guggenheim Securities, LifeSci Capital, Oppenheimer, and H.C. Wainwright.